Evidence map›Paper›PMID 38402867›Full record

ReviewActa haematologica2024

Oncogenic MTOR Signaling Axis Compensates BTK Inhibition in a Chronic Lymphocytic Leukemia Patient with Richter Transformation: A Case Report and Review of the Literature.

Thomas Parigger, Stephan Drothler, Christian Scherhäufl, Franz Josef Gassner, Maria Schubert, Markus Steiner, Jan Philip Höpner, Alexandra Hödlmoser, Lena Schultheis, Aryunni Abu Bakar and 6 more

Abstract readCase ReportsReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Acta haematologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Thomas PariggerDepartment of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute - Laboratory for Immunological and Molecular Cancer Research (LIMCR), Paracelsus Medical University, Cancer Cluster Salzburg, Salzburg, Austria.
Stephan DrothlerDepartment of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute - Laboratory for Immunological and Molecular Cancer Research (LIMCR), Paracelsus Medical University, Cancer Cluster Salzburg, Salzburg, Austria.
Christian ScherhäuflDepartment of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute - Laboratory for Immunological and Molecular Cancer Research (LIMCR), Paracelsus Medical University, Cancer Cluster Salzburg, Salzburg, Austria.
Franz Josef GassnerDepartment of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute - Laboratory for Immunological and Molecular Cancer Research (LIMCR), Paracelsus Medical University, Cancer Cluster Salzburg, Salzburg, Austria.
Maria SchubertDepartment of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute - Laboratory for Immunological and Molecular Cancer Research (LIMCR), Paracelsus Medical University, Cancer Cluster Salzburg, Salzburg, Austria.
Markus SteinerDepartment of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute - Laboratory for Immunological and Molecular Cancer Research (LIMCR), Paracelsus Medical University, Cancer Cluster Salzburg, Salzburg, Austria.
Jan Philip HöpnerDepartment of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute - Laboratory for Immunological and Molecular Cancer Research (LIMCR), Paracelsus Medical University, Cancer Cluster Salzburg, Salzburg, Austria.
Alexandra HödlmoserDepartment of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute - Laboratory for Immunological and Molecular Cancer Research (LIMCR), Paracelsus Medical University, Cancer Cluster Salzburg, Salzburg, Austria.
Lena SchultheisDepartment of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute - Laboratory for Immunological and Molecular Cancer Research (LIMCR), Paracelsus Medical University, Cancer Cluster Salzburg, Salzburg, Austria.
Aryunni Abu BakarDepartment of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute - Laboratory for Immunological and Molecular Cancer Research (LIMCR), Paracelsus Medical University, Cancer Cluster Salzburg, Salzburg, Austria.
Daniel NeureiterInstitute of Pathology, Paracelsus Medical University, Salzburg, Austria.
Lisa PleyerDepartment of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute - Laboratory for Immunological and Molecular Cancer Research (LIMCR), Paracelsus Medical University, Cancer Cluster Salzburg, Salzburg, Austria.
Alexander EgleDepartment of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute - Laboratory for Immunological and Molecular Cancer Research (LIMCR), Paracelsus Medical University, Cancer Cluster Salzburg, Salzburg, Austria.
Richard GreilDepartment of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute - Laboratory for Immunological and Molecular Cancer Research (LIMCR), Paracelsus Medical University, Cancer Cluster Salzburg, Salzburg, Austria.
Roland GeisbergerDepartment of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute - Laboratory for Immunological and Molecular Cancer Research (LIMCR), Paracelsus Medical University, Cancer Cluster Salzburg, Salzburg, Austria.
Nadja ZaborskyDepartment of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute - Laboratory for Immunological and Molecular Cancer Research (LIMCR), Paracelsus Medical University, Cancer Cluster Salzburg, Salzburg, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTargeting the B-cell receptor pathway via ibrutinib, a specific inhibitor of Bruton's tyrosine kinase, has shown marked clinical efficacy in treatment of patients with chronic lymphocytic leukemia (CLL), thus becoming a preferred first line option independent of risk factors. However, acquired resistance to ibrutinib poses a major clinical problem and requires the development of novel treatment combinations to increase efficacy and counteract resistance development and clinical relapse rates. CASE PRESENTATION: In this study, we performed exome and transcriptome analyses of an ibrutinib resistant CLL patient in order to investigate genes and expression patterns associated with ibrutinib resistance. Here, we provide evidence that ibrutinib resistance can be attributed to aberrant mammalian target of rapamycin (MTOR) signaling.

conclusionThus, our study proposes that combined use of MTOR inhibitors with ibrutinib could be a possible option to overcome therapy resistance in ibrutinib treated patients.

Indexed as

AdenineAgammaglobulinaemia Tyrosine KinaseDrug Resistance, NeoplasmLeukemia, Lymphocytic, Chronic, B-CellPiperidinesProtein Kinase InhibitorsSignal TransductionTOR Serine-Threonine KinasesHumansMalePyrazolesPyrimidinesAdenineAgammaglobulinaemia Tyrosine KinaseBTK protein, humanibrutinibMTOR protein, humanPiperidinesProtein Kinase InhibitorsPyrazolesPyrimidinesTOR Serine-Threonine KinasesChronic lymphocytic leukemiaIbrutinibmTORMutational analysisResistance mechanismTranscriptome (RNA-Seq)

Identifiers

PMID38402867
PMCPMC11441378

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.